Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies

摘要 要求支持一次题为“纤维化发病机制和解决办法： 从机制到治疗，由大卫拉加雷斯，鲍里斯欣茨和卡林布斯塔尼博士组织。的 会议将于2023年3月19日至23日在加拿大阿尔伯塔省班夫举行。 人类纤维化疾病的特征在于响应于压倒性的或非压倒性的炎症反应的进行性组织瘢痕形成。 慢性损伤，最终导致器官衰竭和死亡。纤维化疾病导致医疗费用达到 每年100亿美元。这些成本预计将进一步增加，随着我们的人口老龄化，我们的增长， 诊断纤维化疾病的能力和新的传染源如SARS-CoV-2的出现， 其可促进纤维化的发展。因此，本次会议旨在确定共同的 以及响应于不同损伤而驱动纤维化的不同机制（例如，病毒感染、创伤、致癌 伤害）。这次会议还将讨论该领域的下列新主题： 扩大和延续组织纤维化，如老化，表观遗传学和机械生物学，2） 组织修复和纤维化中的成纤维细胞异质性，以及3）理解促进纤维化的机制 解决和再生，以制定新的战略，真正再生纤维化器官。本次论坛还将 重点关注主要的临床挑战，包括缺乏稳健的纤维化生物标志物、安全性终点和临床 试验终点。这些领域的进展将打破将抗纤维化疗法从 长凳到床边这次Keystone研讨会会议将加速纤维化研究和抗纤维化药物 通过促进不同群体的医生和科学家之间的跨学科互动， 学术机构和制药和生物技术行业。最后，本次大会将在 与代谢和NAFLD/NASH的分子机制。联合会议将突出当前 NASH和肝纤维化相关的关键生物学过程。的与会者 会议将有机会通过共享会议，用餐时间和晚上的海报网络 sessions.

ABSTRACT Support is requested for a Keystone Symposia conference entitled Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies, organized by Drs. David Lagares, Boris Hinz and Carine Boustany. The conference will be held in Banff, Alberta, Canada from March 19 - 23, 2023. Human fibrotic diseases are characterized by progressive tissue scarring in response to overwhelming or chronic injury, ultimately leading to organ failure and death. Fibrotic diseases cause healthcare costs reaching $10 billion per year. These costs are expected to further increase with our aging populations, our increasing capacity to diagnose fibrotic disorders and the emergence of novel infectious agents such as SARS-CoV-2, which can promote the development of fibrosis. Therefore, this conference was designed to identify common and distinct mechanisms driving fibrosis in response to different insults (e.g., viral infection, trauma, oncogenic injury). This conference will also address the following emerging themes in the field: 1) the mechanisms which amplify and perpetuate tissue fibrosis, such as aging, epigenetics, and mechanobiology, 2) the relevance of fibroblast heterogeneity in tissue repair and fibrosis, and 3) understanding the mechanisms promoting fibrosis resolution and regeneration to devise novel strategies to truly regenerate fibrotic organs. This forum will also focus on major clinical challenges including the lack of robust fibrosis biomarkers, safety endpoints, and clinical trial endpoints. Advances in these areas will break down barriers in translating anti-fibrotic therapies from bench to bedside. This Keystone Symposia conference will accelerate fibrosis research and anti-fibrotic drug discovery by fostering interdisciplinary interactions among a diverse group of physicians and scientists from both academic institutions and the pharmaceutical and biotech industry. Finally, this conference will be held jointly with Metabolic and Molecular Mechanisms of NAFLD/NASH. The joint conference will highlight current evidence linking key biological processes involved in NASH and liver fibrosis. Participants from both conferences will have the opportunity to network through shared sessions, mealtimes, and evening poster sessions.